Robert Negrin
Publications
- A distinct evolution of the T cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood. 2013
- Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. Proc Natl Acad Sci U S A. 2012; (15): 5820-5
- Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant. 2012; (1): 125-33
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012; (25): 6145-54
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood. 2012; (24): 5758-68
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012; (4): 581-8
- Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; (11): 1679-87
- Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant. 2011; (7): 1051-7
- CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. Blood. 2011; (11): 3230-9
- Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant. 2011; (2): 192-9
- Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood. 2011; (11): 3220-9
- Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation. Biol Blood Marrow Transplant. 2011; (1 Suppl): S58-62
- Role of regulatory T cell populations in controlling graft vs host disease. Best Pract Res Clin Haematol. 2011; (3): 453-7
- Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell. 2011; (3): 309-17
- Biology and clinical effects of natural killer cells in allogeneic transplantation. Curr Opin Oncol. 2010; (2): 130-7
- CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 2010; (24): 10170-81
- Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res. 2010; (23): 9837-45
- Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2010; (2): 279-84
- Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Bone Marrow Transplant. 2010; (2): 303-9
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010; (21): 4293-301
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant. 2010; (8): 1145-54
- Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer. 2009; (1): 239-44
- Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant. 2009; (7): 765-76
- TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009; (5): 1099-109
- Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation. J Immunol. 2009; (5): 3219-28
- Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008; (1): 453-62
- In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008; (6): 2563-74
- Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008; (3): 903-9
- Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008; (7): 741-7
- Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo. J Immunol. 2008; (6): 3811-7
- Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood. 2008; (5): 2919-28
- The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008; (2): 945-53
- Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood. 2007; (5): 2225-33
- Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease. Biol Blood Marrow Transplant. 2007; (12): 1427-38
- In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood. 2007; (6): 2649-56
- Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007; (13): 4588-98
- Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation. Curr Stem Cell Res Ther. 2006; (2): 203-12
- Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res. 2006; (6): 1859-67
- High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2006; (7): 703-11
- In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Nat Rev Immunol. 2006; (6): 484-90
- Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006; (1): 390-9
- Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006; (10): 995-1009
- Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006; (5768): 1780-4
- A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005; (3): 181-7
- Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation. Am J Pathol. 2005; (5): 1321-31
- Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med. 2005: 509-38
- In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005; (3): 1113-22
- Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation. 2005; (1): 134-9
- Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005; (13): 1321-31
- Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 2005; (12): 7819-28
- CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003; (9): 1144-50
- Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003; (2): 640-8
- Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer. 2002; (16): 2128-36
- Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol. 2002; (3): 131-6
- Understanding immune cell trafficking patterns via in vivo bioluminescence imaging. J Cell Biochem Suppl. 2002: 239-48
- Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. Cancer Res. 2002; (20): 5785-91
- Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence. Ann Hematol. 2002: S44-5
- Bioluminescence imaging of lymphocyte trafficking in vivo. Exp Hematol. 2001; (12): 1353-60
- CD31 mismatching affects marrow transplantation outcome. Biol Blood Marrow Transplant. 2001; (9): 503-12
- Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant. 2001; (10): 552-60
- Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001; (10): 532-42
- Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001; (10): 2923-31
- Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2001; (4): 216-22
- High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001; (2): 404-9
- High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant. 2001; (5): 294-301
- Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies. Cancer. 2001; (12): 2205-13
- Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett. 2001; (3): 169-73
- Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia. 2000 Jan-Apr; (1-2): 41-52
- CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood. 2000; (12): 3827-37
- Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant. 2000; (5): 506-12
- Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. Biol Blood Marrow Transplant. 2000; (1): 58-69
- High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000; (3A): 352-8
- Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000; (4): 387-94
- Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother. 2000; (6): 335-45
- Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000; (5A): 555-62
- Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant. 2000; (3): 262-71
- A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Clin Cancer Res. 1999; (11): 3411-8
- Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. Biol Blood Marrow Transplant. 1999; (5): 285-91
- Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol Blood Marrow Transplant. 1999; (5): 299-305
- Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia. 1999; (4): 303-10
- Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A. 1999; (21): 12044-9
- Engraftment of chronic myeloid leukemia in SCID mice. Hematol Oncol. 1998; (3): 87-100
- Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998; (9): 3318-27
- Minimal residual disease. Curr Opin Hematol. 1998; (6): 488-93
- Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 1997; (3): 113-21
- Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant. 1997; (6): 324-30
- Granulocyte colony-stimulating factor-induced comobilization of CD4- CD8- T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors. Blood. 1997; (7): 2586-95
- High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 1997; (3): 801-13
- Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol. 1997; (1): 18-25
- Enrichment of allogeneic CD34+ cells and T cell depletion by percoll density gradient centrifugation. Bone Marrow Transplant. 1996: S31-3
- High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. Cancer. 1996; (12): 2502-9
- Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 1996; (2): 76-85
- Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996; (10): 4076-81
- Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant. 1996; (2): 86-92
- Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996; (3): 457-70
- A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer. 1995; (6): 1354-9
- Effects of granulocyte colony-stimulating factor therapy on in vitro hemopoiesis in myelodysplastic syndromes. Leukemia. 1995; (1): 30-9
- Enrichment of bone marrow and blood progenitor (CD34+) cells by density gradients with sufficient yields for transplantation. Exp Hematol. 1995; (9): 1024-9
- Is nitrous oxide safe for bone marrow harvest? Anesth Analg. 1995; (4): 770-2
- Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer. 1995; (5): 860-8
- Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood. 1995; (11): 3334-41
- Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood. 1995; (9): 3493-9
- A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994; (4): 1687-96
- A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood. 1994; (10): 2823-8
- Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations. J Clin Oncol. 1994; (5): 1021-7
- Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol. 1994; (12): 2552-8
- Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood. 1994; (5): 1680-4
- Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994: S9-10
- The role of N-linked carbohydrate residues in lymphokine-activated killer cell-mediated cytolysis. Cell Immunol. 1994; (1): 95-110
- Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood. 1993; (2): 319-23
- Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993; (17): 1225-30
- Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood. 1993; (8): 2031-5
- Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993; (13): 1673-9
- The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. Leukemia. 1993; (10): 1491-5
- Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood. 1993; (3): 737-43
- Use and toxicity of the colony-stimulating factors. Drug Saf. 1993; (6): 457-68
- Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood. 1992; (3): 825-30
- In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. Transfusion. 1992; (1): 42-5
- The use of colony stimulating factors in clinical bone marrow transplantation. Curr Opin Immunol. 1992; (5): 567-70
- Therapy of hematopoietic disorders with recombinant colony-stimulating factors. Adv Pharmacol. 1992: 263-96
- Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging. J Hematother. 1992; (4): 361-8
- The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol. 1991: 47-50
- Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991; (1): 139-49
- Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood. 1991; (3): 654-60
- Bone marrow transplantation for hematologic malignancies: the Stanford experience. Clin Transpl. 1990: 157-63
- Effects of CSFs in preleukemia. Bone Marrow Transplant. 1990: 121-6
- Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Int J Cell Cloning. 1990: 293-300; discussion 300-2
- Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes. Leukemia. 1990; (3): 193-202
- Effects of treatment of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor. Prog Clin Biol Res. 1990: 151-61
- Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. Blood. 1990; (7): 1299-307
- Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 1990; (1): 36-43
- The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes. Cancer Surv. 1990; (1): 199-212
- Lymphokine-activated killer cell activity after cryopreservation. J Immunol Methods. 1989; (1-2): 185-9
- Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. Ann Intern Med. 1989; (12): 976-84
- Nasal continuous positive airway pressure in atelectasis. Chest. 1987; (4): 621-4
Help
Trial Administration